More about Wiskott-Aldrich Syndrome
The classic triad includes microthrombocytopenia (platelets that are both too few and unusually small; about half of patients have counts under 20,000/µL at diagnosis), eczema with severe pruritus, and recurrent infections from bacterial, viral, and opportunistic organisms.
Keep reading about Wiskott-Aldrich Syndrome
Patients develop progressive T-cell immunodeficiency with diminished T-cell numbers and function, combined B-cell dysfunction, and impaired mucosal immunity. Progressive features include autoimmune manifestations (autoimmune hemolytic anemia, vasculitis, arthritis, inflammatory bowel disease) reported in 26-72% of patients across studies, including 72% of 55 patients in a French series (Dupuis-Girod et al., Pediatrics 2003).
Cancer, most often B-cell lymphoma, developed in 13% of patients (21 of 154) in a US survey (Sullivan et al., J Pediatr 1994, as summarized by Hosahalli Vasanna et al., 2021), and people with WAS who have autoimmune problems face a higher risk. Diagnosis combines clinical features, flow cytometry showing small platelet size and reduced/absent WASp protein in lymphocytes, and genetic testing identifying WAS gene mutations. Without a transplant or gene therapy, classic WAS shortens life. In an older National Institutes of Health series, patients who had neither a transplant nor spleen removal had a median survival of less than 5 years (Mullen et al., Blood 1993), and the median survival of all 55 patients in a French series was 14.5 years (Dupuis-Girod et al., Pediatrics 2003).
What are the symptoms of Wiskott-Aldrich Syndrome?
These are common symptoms of Wiskott-Aldrich Syndrome, and how strong they are varies from person to person.
- Severe thrombocytopenia with petechiae and bleeding
- Eczema with pruritus
- Recurrent infections (bacterial, viral, fungal)
- Autoimmune manifestations
- Significantly increased malignancy risk
- Lymphopenia and abnormal T-cell function
Who gets Wiskott-Aldrich Syndrome?
Exclusively males due to X-linked inheritance affecting essentially all hemizygous males, though rare manifesting heterozygous females with extreme lyonization reported. Manifests in infancy with bleeding tendency evident from newborn period and infections developing within first months of life.
Median age at diagnosis has ranged from under 2 months to 24 months across studies (Hosahalli Vasanna et al., 2021). Affects all ethnic and racial groups with estimated incidence of 1 to 10 per million males (MedlinePlus Genetics). Female carriers typically asymptomatic but can transmit disease to male offspring. No geographic variation in incidence. Not associated with familial clustering except through carrier female relatives.
Next steps: find trials you might fitsee approved treatmentsget help payingget alerts
Which medicines are FDA-approved for Wiskott-Aldrich Syndrome?
There are currently 2 FDA-approved medications for Wiskott-Aldrich Syndrome.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
How to get help paying for Wiskott-Aldrich Syndrome treatment
Charity funds and drugmaker programs for Wiskott-Aldrich Syndrome, checked at the source.
- From a charity · The Assistance FundPrimary Immunodeficiency fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Wiskott-Aldrich Syndrome
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Wiskott-Aldrich Syndrome resources
Reputable organizations and medical references for learning more about Wiskott-Aldrich Syndrome, including disease registries, foundation resources, and clinical guidelines.
- Wiskott-Aldrich Foundation
- MedlinePlus Genetics - Wiskott-Aldrich syndrome
- Hosahalli Vasanna et al., J Multidiscip Healthc 2021 - Clinical Features, Cancer Biology, Transplant Approach and Other Integrated Management Strategies for Wiskott-Aldrich Syndrome
- Burroughs et al., Blood 2020 - Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
- Dupuis-Girod et al., Pediatrics 2003 - Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients
- Mullen et al., Blood 1993 - Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases
- Rivers et al., J Allergy Clin Immunol Pract 2019 - Bleeding and splenectomy in Wiskott-Aldrich syndrome: A single-centre experience
- NORD - WAS-Related Disorders